Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

NCT02527200 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide helps children and teenagers with Prader-Willi syndrome manage their weight by measuring changes in their body mass index over 16 weeks.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 56 people

Who can join Ages 6–18 · all sexes

Timeline Started 2015-11 · est. completion 2020-11

Where 32 sites · Australia, Canada, France, Italy, Netherlands, New Zealand, Turkey (Türkiye), United States

What this study is testing ClinicalTrials.gov NCT02527200 ↗

Description as written by the study sponsor.

This trial is conducted globally. The aim of this trial is to investigate the effect of liraglutide for weight management in paediatric subjects with Prader-Willi Syndrome.

Treatments tested

liraglutide Drug

Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
placebo Drug

Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.

Main thing measured	Change in Body Mass Index (BMI) Standard Deviation Score (SDS) From Baseline to 16 Weeks
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02527200 ↗